𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Targeted therapy in head and neck cancer : State of the art 2007 and review of clinical applications

✍ Scribed by Corey J. Langer

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
174 KB
Volume
112
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

In patients with squamous cell carcinoma of the head and neck (SCCHN), tumor recurrence, secondary tumors, and comorbidities contribute to therapy failure, and treatment approaches often are limited by their toxicity. With the incorporation of targeted therapies, the number of options available for patients with SCCHN is growing. The epidermal growth factor receptor (EGFR) is involved in the development and progression of SCCHN and is associated with a poor prognosis. The anti‐EGFR monoclonal antibody (MoAb) cetuximab is the first targeted therapy to be developed for SCCHN. Recent data confirmed a survival advantage and enhanced locoregional control of SCCHN with cetuximab plus radiotherapy (RT) in patients with locally advanced (LA) SCCHN. Single‐agent cetuximab conferred clinical benefits for patients with platinum‐refractory metastatic disease, and a recent phase 3 trial demonstrated a survival benefit with cetuximab and standard platinum‐based therapy in the front‐line treatment of recurrent/metastatic disease. Cetuximab has a toxicity profile milder than that of cytoxic agents and does not exacerbate RT toxicity when it is used in combination. Small‐molecule EGFR‐tyrosine kinase inhibitors also have shown promise in combination with chemoradiotherapy or as single agents, although they are in earlier stages of developmental. Other targeted approaches (eg, antiangiogenics) are also under investigation. Ongoing clinical trials will further define targeted treatment roles in all stages of SCCHN. Cancer 2008. © 2008 American Cancer Society.

📜 SIMILAR VOLUMES

Chemotherapy and targeted therapy in ade
Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: A review
✍ Giorgos Papaspyrou; Stephan Hoch; Alessandra Rinaldo; Juan P. Rodrigo; Robert P. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

## Abstract Adenoid cystic carcinoma (ACC) is an uncommon tumor usually arising in the head and neck region, mainly in the salivary glands. It demonstrates an indolent prolonged course and is characterized by perineural invasion. Primary treatment of local and locoregional disease consists mainly o

Targeted therapies in squamous cell carc
Targeted therapies in squamous cell carcinoma of the head and neck
✍ Kathryn A. Gold; Ho-Young Lee; Edward S. Kim 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 2 views

## Abstract Head and neck cancer is a challenging disease that is expected to account for greater than 500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy and radiation for head and neck cancer, and the prognosis for patients with recurrent and/or metastatic disease r

Unequal burden of head and neck cancer i
Unequal burden of head and neck cancer in the United States
✍ W. Jarrard Goodwin; Giovana R. Thomas; Dorothy F. Parker; Debbie Joseph; Silvina 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 330 KB 👁 2 views

## Abstract ## Background. Black Americans are adversely affected by many types of malignancies. ## Methods. We reviewed data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program to evaluate racial disparities in head and neck cancer incidence, mortalit

TNM-based stage groupings in head and ne
TNM-based stage groupings in head and neck cancer: Application in cancer of the hypopharynx
✍ Stephen F. Hall; Patti A. Groome; Jonathan Irish; Brian O'Sullivan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

## Abstract ## Background. The purpose of this study was to test the Union Internationale Contre le Cancer (UICC)/TNM category–based head and neck cancer stage grouping systems proposed in the literature for their ability to create clinically relevant prognostic groups of like‐patients with cancer

Neck dissection in the combined-modality
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer
✍ Athanassios Argiris; Kerstin M. Stenson; Bruce E. Brockstein; Bharat B. Mittal; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 1 views

## Abstract ## Purpose. The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck. ## Methods. We identified patients with N2–N3 head and neck cancers who were enrolled in three consecutive mul

Management of the clinically negative ne
Management of the clinically negative neck in early-stage head and neck cancers after transoral resection
✍ Juan P. Rodrigo; Jatin P. Shah; Carl E. Silver; Jesus E. Medina; Robert P. Takes 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB 👁 1 views

## Abstract The decision regarding treatment of the clinically negative neck has been debated extensively. This is particularly true with early‐stage tumors for which surgery is the treatment of choice, and the tumor has been resected transorally without a cervical incision. Elective neck dissectio